Industry sponsor intelligence

sigma-tau i.f.r. S.p.A.Clinical Pipeline.

Lead-sponsor view of sigma-tau i.f.r. S.p.A.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.

Total: 3
Recruiting: 0
Active: 0
Completed: 3
Results posted: 1
Avg enrollment: 387

Pipeline overview

Programs by phase and activity.

Velocity

sigma-tau i.f.r. S.p.A. trials by start year

Study start year · indexed snapshot

Development

Trials by phase

3phase labels

Early Phase 10

Phase 10

Phase 22

Phase 31

Phase 40

Product	Studies	Early / I	Phase II	Phase III	Phase IV	Active
Thymosin Alpha-1 →	3	0	2	1	0	0

Active peptide trials

In motion now.

No studies in this snapshot.

Completed trials

Finished registry records.

NCT IDStudyPhase / statusEnrollmentUpdated

NCT01031966

A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine

sigma-tau i.f.r. S.p.A. · END STAGE RENAL DISEASE

Phase 2

Completed

120

2012-03

NCT01178996

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

sigma-tau i.f.r. S.p.A. · Chronic Hepatitis C

Phase 3

Completed

552

2010-08

NCT00911443

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

sigma-tau i.f.r. S.p.A. · Malignant Melanoma

Phase 2

Completed

488

2009-07

Search sponsor records

All sigma-tau i.f.r. S.p.A. studies.

This page groups studies where sigma-tau i.f.r. S.p.A. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.